Clinical trials: Atopic Asthma
Asthma, Allergic Rhinitis
PF and FeNO and Clinical Characteristics in Children Being Diagnosed Due to Suspicion of Allergic Diseases
The aim of this study is to assess the influence of kind of allergic disease, allergic profile, allergen exposure, treatment method on lung function parameters, fractional exhaled nitric oxide level in children suspected and…
- Conditions
- Asthma, Allergic Rhinitis, Atopic Dermatitis, Urticaria
- Trial name
- NCT01805635
- Testing
- No intervention
- Where
- Poland
- Volunteers
- 5,500 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
Allergic Asthma
A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)
This is a randomized, double-blind, placebo-controlled, crossover study comparing asthma control post treatment in African American/Black and Caucasian/White children in both hyper and hypo responsive HILD (Histamine…
- Trial name
- HAS3 (NCT04699604)
- Testing
- Levocetirizine Dihydrochloride
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Bridgette Jones
Atopic Asthma, Recurrent Wheezing
Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants
The primary objective of the study is to determine whether the incidence of atopic asthma after three years old may be suppressed in the children who were born as preterm infants and prophylactically treated with palivizumab for…
- Trial name
- NCT01545245
- Volunteers
- 343 people
- Sponsor
- Tokai University
Immune Deficiency, Immune Dysregulation Disorder
Allergy and Immunology Natural History Study
This protocol is a natural history study designed to evaluate subjects (and some family members) with suspected or identified genetic diseases of allergic inflammation or Immune Dysregulation.
- Conditions
- Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
- Trial name
- NCT05584488
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Moderate to Severe Allergic Asthma
A Clinical Study of Omalizumab in the Treatment of Allergic Asthma(ESSENCE)
Allergic asthma being the most widespread and easily identifiable phenotype, accounting for 60-80% of cases.Previous studies have reported that nearly 90% of patients with severe asthma were cases of allergic asthma, in which…
- Trial name
- ESSENCE (NCT06348407)
- Testing
- IgE monoclonal antibody
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Asthma
XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States
A retrospective database pre-post cohort study, identifying asthmatic patients, aged 6- 11, with omalizumab use over 24 months
- Trial name
- NCT05157087
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 16,246 people
- Sponsor
- Novartis Pharmaceuticals
Immunotherapy, Allergy and Immunology
MAPS & ITEC Cohorts: 6-8 Years Follow-up
This study represents the follow-up, age 6-8 years, of children recruited at birth into two cohorts. The first cohort, the Mite Allergen Prevention Study (MAPS) was a double-blind, randomized controlled trial of the use of house…
- Conditions
- Immunotherapy, Allergy and Immunology, Asthma
- Trial name
- NCT03763630
- Testing
- House dust-mite SLIT, Normal saline
- Where
- 2 sites in United Kingdom
- Volunteers
- 263 people
- Sponsor
- University of Southampton
Asthma
Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma
This study will assess further the safety and tolerability of long-term treatment with omalizumab by extending omalizumab treatment by 1 year for those patients with allergic asthma who successfully completed study CIGE25011E2.
- Trial name
- NCT00482248
- Testing
- Omalizumab
- Volunteers
- 132 people
- Sponsor
- Novartis